{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:51:31Z","timestamp":1776358291405,"version":"3.51.2"},"reference-count":111,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":803,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","journals.elsevierhealth.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.ajpath.2017.04.021","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T13:47:16Z","timestamp":1500472036000},"page":"2185-2198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Evolving Role of Companion Diagnostics for Breast Cancer in an Era of Next-Generation Omics"],"prefix":"10.1016","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7969-7423","authenticated-orcid":false,"given":"Jason N.","family":"Rosenbaum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Weisman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2017.04.021_bib1","series-title":"Molecular Oncology Testing for Solid Tumors: A Pragmatic Approach","first-page":"269","article-title":"Breast tumors","author":"Uram-Tuculescu","year":"2015"},{"key":"10.1016\/j.ajpath.2017.04.021_bib2","first-page":"1431","article-title":"Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer","volume":"60","author":"Lerner","year":"1976","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.ajpath.2017.04.021_bib3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.1983.1.4.227","article-title":"Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer","volume":"1","author":"Fisher","year":"1983","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1056\/NEJM198902233200802","article-title":"A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors","volume":"320","author":"Fisher","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM198107023050101","article-title":"Treatment of primary breast cancer with chemotherapy and tamoxifen","volume":"305","author":"Fisher","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.5858\/arpa.2013-0566-CP","article-title":"Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast","volume":"138","author":"Fitzgibbons","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib7","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.1999.17.5.1474","article-title":"Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer","volume":"17","author":"Harvey","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib8","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2017.04.021_bib9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2017.04.021_bib10","first-page":"4744","article-title":"Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells","volume":"61","author":"Molina","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2017.04.021_bib11","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1358\/dot.1999.35.12.564040","article-title":"Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer","volume":"35","author":"Albanell","year":"1999","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.ajpath.2017.04.021_bib12","series-title":"Diagnostic Molecular Pathology: A Guide to Applied Molecular Testing","first-page":"257","article-title":"Molecular testing in breast cancer","author":"Allison","year":"2017"},{"key":"10.1016\/j.ajpath.2017.04.021_bib13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00129039-200206000-00015","article-title":"Effect of prolonged formalin fixation on the immunohistochemical reactivity of breast markers","volume":"10","author":"Arber","year":"2002","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2325\/jbcs.976","article-title":"The effects of fixation, processing and evaluation criteria on immunohistochemical detection of hormone receptors in breast cancer","volume":"14","author":"Oyama","year":"2007","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ajpath.2017.04.021_bib15","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/modpathol.2012.59","article-title":"The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma","volume":"25","author":"Yildiz-Aktas","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib16","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/jnci\/djs438","article-title":"Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues","volume":"104","author":"Neumeister","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ajpath.2017.04.021_bib17","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1309\/AJCPB1RIT5YXMRIS","article-title":"The effect of delay in fixation, different fixatives, and duration of fixation in estrogen and progesterone receptor results in breast carcinoma","volume":"135","author":"Apple","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/path.1077","article-title":"Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue","volume":"197","author":"Skliris","year":"2002","journal-title":"J Pathol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib19","first-page":"716","article-title":"Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies","volume":"109","author":"McCarty","year":"1985","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib20","doi-asserted-by":"crossref","first-page":"930","DOI":"10.5858\/134.6.930","article-title":"Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays","volume":"134","author":"Fitzgibbons","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib21","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.5858\/134.7.e48","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)","volume":"134","author":"Hammond","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.5858\/arpa.2012-0442-RA","article-title":"Theranostic and molecular classification of breast cancer","volume":"138","author":"Cornejo","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/01.pai.0000209866.20581.8e","article-title":"Effects of fixative and fixation protocols on assessment of Her-2\/neu oncogene amplification status by fluorescence in situ hybridization","volume":"15","author":"Willmore-Payne","year":"2007","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib25","doi-asserted-by":"crossref","first-page":"djv136","DOI":"10.1093\/jnci\/djv136","article-title":"Measurement of domain-specific HER2 (ERBB2) expression may classify benefit from trastuzumab in breast cancer","volume":"107","author":"Carvajal-Hausdorf","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ajpath.2017.04.021_bib26","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5858\/arpa.2016-0201-OA","article-title":"RAI1 alternate probe identifies additional breast cancer cases as amplified following equivocal HER2 fluorescence in situ hybridization testing: experience from a National Reference Laboratory","volume":"141","author":"Hui","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nature10933","article-title":"The clonal and mutational evolution spectrum of primary triple-negative breast cancers","volume":"486","author":"Shah","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2017.04.021_bib28","doi-asserted-by":"crossref","first-page":"11479","DOI":"10.1038\/ncomms11479","article-title":"The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes","volume":"7","author":"Pereira","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2017.04.021_bib29","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/modpathol.2012.36","article-title":"Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance","volume":"25","author":"Seol","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib30","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/ng.2823","article-title":"Activating ESR1 mutations in hormone-resistant metastatic breast cancer","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ajpath.2017.04.021_bib31","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ajpath.2017.04.021_bib32","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.1158\/0008-5472.CAN-13-1197","article-title":"D538G mutation in estrogen receptor-alpha: a novel mechanism for acquired endocrine resistance in breast cancer","volume":"73","author":"Merenbakh-Lamin","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2017.04.021_bib33","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-13-2332","article-title":"Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer","volume":"20","author":"Jeselsohn","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2017.04.021_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevOncog.v17.i1.20","article-title":"Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications","volume":"17","author":"Rexer","year":"2012","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.ajpath.2017.04.021_bib35","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s10549-013-2648-1","article-title":"Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics","volume":"140","author":"Groenendijk","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajpath.2017.04.021_bib36","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer","volume":"3","author":"Bose","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2017.04.021_bib37","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1158\/1078-0432.CCR-13-0295","article-title":"Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations","volume":"19","author":"Ross","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2017.04.021_bib38","doi-asserted-by":"crossref","first-page":"14476","DOI":"10.1073\/pnas.1203201109","article-title":"Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2","volume":"109","author":"Greulich","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2017.04.021_bib39","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cell.2015.09.033","article-title":"Comprehensive molecular portraits of invasive lobular breast cancer","volume":"163","author":"Ciriello","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ajpath.2017.04.021_bib40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature11154","article-title":"Sequence analysis of mutations and translocations across breast cancer subtypes","volume":"486","author":"Banerji","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2017.04.021_bib41","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature11017","article-title":"The landscape of cancer genes and mutational processes in breast cancer","volume":"486","author":"Stephens","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2017.04.021_bib42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2017.04.021_bib43","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.ajpath.2017.04.021_bib44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2017.04.021_bib45","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/modpathol.2016.39","article-title":"Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology","volume":"29","author":"Weisman","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib46","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature17676","article-title":"Landscape of somatic mutations in 560 breast cancer whole-genome sequences","volume":"534","author":"Nik-Zainal","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2017.04.021_bib47","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1200\/JCO.2011.37.8133","article-title":"Breast and ovarian cancer risk and risk reduction in Jewish BRCA1\/2 mutation carriers","volume":"30","author":"Finkelman","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib48","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/cam4.748","article-title":"Detection of somatic BRCA1\/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases","volume":"5","author":"Koczkowska","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib49","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/bjc.2014.345","article-title":"Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours","volume":"111","author":"Del Conte","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2017.04.021_bib50","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/annonc\/mdu187","article-title":"Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors","volume":"25","author":"Balmana","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib51","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib52","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2017.04.021_bib53","first-page":"519","article-title":"An update on PARP inhibitors for the treatment of cancer","volume":"8","author":"Benafif","year":"2015","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ajpath.2017.04.021_bib54","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1158\/1078-0432.CCR-14-0571","article-title":"Functional ex\u00a0vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment","volume":"20","author":"Naipal","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2017.04.021_bib55","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2017.04.021_bib56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1078-0432.CCR-16-0134","article-title":"A phase Ib study of alpelisib (BYL719), a PI3Kalpha-specific inhibitor, with letrozole in ER+\/HER2- metastatic breast cancer","volume":"23","author":"Mayer","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2017.04.021_bib57","doi-asserted-by":"crossref","first-page":"R21","DOI":"10.1186\/bcr2833","article-title":"Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer","volume":"13","author":"Sanchez","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ajpath.2017.04.021_bib58","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s10637-014-0082-9","article-title":"Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors","volume":"32","author":"Rodon","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ajpath.2017.04.021_bib59","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2014.55.7876","article-title":"PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer","volume":"32","author":"Loibl","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib60","doi-asserted-by":"crossref","first-page":"19257","DOI":"10.3390\/ijms140919257","article-title":"The consequence of oncomorphic TP53 mutations in ovarian cancer","volume":"14","author":"Brachova","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajpath.2017.04.021_bib61","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In\u00a0vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2017.04.021_bib62","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1073\/pnas.0708917105","article-title":"Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition","volume":"105","author":"Shangary","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2017.04.021_bib63","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2174\/09298673113206660325","article-title":"Targeting MDM2-p53 interaction for cancer therapy: are we there yet?","volume":"21","author":"Nag","year":"2014","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ajpath.2017.04.021_bib64","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1158\/1078-0432.CCR-07-5136","article-title":"Targeting the MDM2-p53 interaction for cancer therapy","volume":"14","author":"Shangary","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2017.04.021_bib65","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib66","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13058-016-0721-5","article-title":"Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1\/TRIO-18","volume":"18","author":"Finn","year":"2016","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ajpath.2017.04.021_bib67","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","article-title":"FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)","volume":"38","author":"Katoh","year":"2016","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib68","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1200\/JCO.2012.43.7251","volume":"31","author":"Yardley","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib69","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective validation of a 21-gene expression assay in breast cancer","volume":"373","author":"Sparano","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib70","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djr393","article-title":"Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group","volume":"103","author":"Dowsett","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ajpath.2017.04.021_bib71","doi-asserted-by":"crossref","first-page":"7212","DOI":"10.1200\/JCO.2005.07.501","article-title":"Proliferation marker Ki-67 in early breast cancer","volume":"23","author":"Urruticoechea","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib72","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jnci\/djk020","article-title":"Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer","volume":"99","author":"Dowsett","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ajpath.2017.04.021_bib73","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1158\/1078-0432.CCR-11-0926","article-title":"A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors","volume":"17","author":"Filipits","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2017.04.021_bib74","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/jnci\/djn309","article-title":"Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics","volume":"100","author":"Ellis","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ajpath.2017.04.021_bib75","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/modpathol.2016.34","article-title":"Digital image analysis outperforms manual biomarker assessment in breast cancer","volume":"29","author":"Stalhammar","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib76","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib77","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2017.04.021_bib78","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib79","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2017.04.021_bib80","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib81","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tips.2016.09.007","article-title":"The evolution of oncology companion diagnostics from signal transduction to immuno-oncology","volume":"38","author":"Dracopoli","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.ajpath.2017.04.021_bib82","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/1758834016658423","article-title":"Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond","volume":"8","author":"Migali","year":"2016","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib83","first-page":"392","article-title":"Checkpoint inhibitors in breast cancer: hype or promise?","volume":"14","author":"McArthur","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib84","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2217\/bmm.14.84","article-title":"Complementary versus companion diagnostics: apples and oranges?","volume":"9","author":"Milne","year":"2015","journal-title":"Biomark Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib85","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5858\/arpa.2015-0522-SA","article-title":"Programmed death ligand-1 immunohistochemistry: friend or foe?","volume":"140","author":"Kerr","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib86","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib87","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib88","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2017.04.021_bib89","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/2326-6066.CIR-16-0143","article-title":"Targeted next generation sequencing identifies markers of response to PD-1 blockade","volume":"4","author":"Johnson","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ajpath.2017.04.021_bib90","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2017.04.021_bib91","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2017.04.021_bib92","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ajpath.2017.04.021_bib93","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib94","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial","volume":"25","author":"Loi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib95","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","article-title":"Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199","volume":"32","author":"Adams","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib96","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","article-title":"Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer","volume":"28","author":"Denkert","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib97","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","article-title":"Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers","volume":"33","author":"Denkert","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib98","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2326-6066.CIR-14-0133","article-title":"PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer","volume":"3","author":"Wimberly","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ajpath.2017.04.021_bib99","doi-asserted-by":"crossref","first-page":"dju435","DOI":"10.1093\/jnci\/dju435","article-title":"Objective measurement and clinical significance of TILs in non-small cell lung cancer","volume":"107","author":"Schalper","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ajpath.2017.04.021_bib100","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib101","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2017.04.021_bib102","doi-asserted-by":"crossref","first-page":"10750","DOI":"10.1073\/pnas.1608077113","article-title":"Leveraging premalignant biology for immune-based cancer prevention","volume":"113","author":"Spira","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2017.04.021_bib103","first-page":"99","article-title":"The current and future state of companion diagnostics","volume":"8","author":"Agarwal","year":"2015","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib104","doi-asserted-by":"crossref","first-page":"196cm6","DOI":"10.1126\/scitranslmed.3005950","article-title":"Breaking a vicious cycle","volume":"5","author":"Hayes","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ajpath.2017.04.021_bib105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1586\/14737159.2016.1117389","article-title":"Companion diagnostic assays for PD-1\/PD-L1 checkpoint inhibitors in NSCLC","volume":"16","author":"Jorgensen","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.ajpath.2017.04.021_bib106","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fbioe.2015.00092","article-title":"Detection of genomic structural variants from next-generation sequencing data","volume":"3","author":"Tattini","year":"2015","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.ajpath.2017.04.021_bib107","doi-asserted-by":"crossref","first-page":"38037","DOI":"10.1038\/srep38037","article-title":"Sequencing-based breast cancer diagnostics as an alternative to routine biomarkers","volume":"6","author":"Rantalainen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajpath.2017.04.021_bib108","doi-asserted-by":"crossref","first-page":"10259","DOI":"10.1038\/ncomms10259","article-title":"Proteomic maps of breast cancer subtypes","volume":"7","author":"Tyanova","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2017.04.021_bib109","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10549-012-2353-5","article-title":"Vimentin DNA methylation predicts survival in breast cancer","volume":"137","author":"Ulirsch","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajpath.2017.04.021_bib110","first-page":"228","article-title":"Bioactive hyaluronan fragment (hexasaccharide) detects specific hexa-binding proteins in human breast and stomach cancer: possible role in tumorogenesis","volume":"49","author":"Srinivas","year":"2012","journal-title":"Indian J Biochem Biophys"},{"key":"10.1016\/j.ajpath.2017.04.021_bib111","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.2869","article-title":"Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry","volume":"11","author":"Giesen","year":"2014","journal-title":"Nat Methods"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000294401730069X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000294401730069X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T16:00:34Z","timestamp":1692892834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000294401730069X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":111,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S000294401730069X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2017.04.021","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Evolving Role of Companion Diagnostics for Breast Cancer in an Era of Next-Generation Omics","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2017.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}